Company Analysis
Sign in

Twist Bioscience Corporation (TWST)

Nasdaq: TWST · Biological Products, (No Diagnostic Substances) · South San Francisco, CA · filing with the SEC since 2013
Full chart Alerts Compare
Grade6.2
◀ Past 7.2● Present 7.6▶ Future 4.4
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$377M+20.3%
Net income-$77.7M+62.8%
Earnings per share$-1.30+63.9%
Operating cash flow-$47.6M+25.7%
Cash$185M-19.1%
Debtn/a
Shareholders’ equity$473M+0.1%
Shares, diluted59.8M+3.1%
Return on equity-16.4%
The recordfrom its filings
Filings in 2026282
Newest filingNov 12 · 8-K
Annual reportNov 17, 2025
Quarterly reportAug 3, 2026
Next report due10-K by Nov 29
Insider sales, 12 months$148M
Insider buys, 12 months$0.00
Patents granted66
Filer categoryLarge accelerated filer
Trailing twelve months to Jun 2026Revenue $432MNet income -$137MCash from operations -$53.1Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Nov 10, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Nov 5, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 5, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 5, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 5, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 5, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton TWST · research, not advice